首页> 外文期刊>Analytical methods >Development of a universal method for the measurement of binding affinities of antibody drugs towards a living cell based on AFM force spectroscopy
【24h】

Development of a universal method for the measurement of binding affinities of antibody drugs towards a living cell based on AFM force spectroscopy

机译:基于AFM力光谱法测定抗体药物结合亲和力的普遍方法的发展

获取原文
获取原文并翻译 | 示例
           

摘要

A universal method to measure the binding affinities of antibody drugs towards their targets on the surface of living cells was developed based on atomic force microscopy (AFM) analysis. Nivolumab, an antibody drug targeting programmed cell death 1 (PD-1), was mainly used as a model for this evaluation. The surface of a tip-less AFM cantilever was coated with nano-capsules, on which immunoglobulin G-binding ZZ domains of protein A were exposed, and nivolumab molecules were immobilized on the cantilever through binding between the antibody Fc domains and the ZZ domains, which controlled the molecular orientation of the antibodies. Model human T lymphocytes (Jurkat), on which PD-1 molecules were highly expressed, were immobilized on a glass substrateviaa lipid bilayer-anchoring reagent. The nivolumab-coated AFM cantilever was moved to approach the T cells, and the rupture forces between nivolumab molecules on the AFM cantilever and PD-1 molecules on the cell surface were measured. The average values of the rupture forces were 0.18 +/- 0.10, 0.21 +/- 0.18, 0.12 +/- 0.07, 0.11 +/- 0.06, and 0.12 +/- 0.06 nN mu m(-2)at loading forces of 10, 20, 30, 40, and 50 nN, respectively. Application of significantly higher loading forces decreased the S/N ratio, as confirmed by comparison with control T cells with low PD-1 expression, which suggested that a low loading force of less than 20 nN was sufficient for these measurements. A correlation between the expression levels of PD-1 and the rupture force values was confirmed using immunofluorescence. A similar assay was performed by using an antibody drug targeting epidermal growth factor receptor (EGFR) and a model cancer cell expressing EGFR molecules (A431) to evaluate the universal application of the developed method for various antibody drugs, and the same conclusions as that in nivolumab's case were obtained. This method can be applied to living cells without any chemical treatment, which allows the present method to compare the affinities of various antibody drugs towards the same single cell. These results indicated that the present method is useful for selecting the most effective candidates from various antibody drugs from the point of view of binding forces between antibodies and living cells.
机译:基于原子力显微镜(AFM)分析,开发了一种衡量抗体药物朝向活细胞表面靶向其靶标的靶向的通用方法。 Nivolumab,靶向细胞死亡1(PD-1)的抗体药物主要用作该评估的模型。将末端AFM悬臂的表面涂覆有纳米胶囊,其中蛋白质A的免疫球蛋白G结合ZZ结构ZZ结构域通过抗体FC结构域和ZZ结构域之间的结合固定在悬臂上,控制抗体的分子取向。模型人体T淋巴细胞(Jurkat),在其上高表达PD-1分子,固定在玻璃基础上的脂质双层锚定试剂上。将Nivolumab涂覆的AFM悬臂移动以接近T细胞,测量Nivolumab分子在细胞表面上的Nivolumab分子之间的破裂力。破裂力的平均值为0.18 +/- 0.10,0.21 +/- 0.18,0.12 +/- 0.07,0.11 +/- 0.06,0.12 +/- 0.06,0.12 +/- 0.06,0.12 +/- 0.06 nn mu m(-2)分别为20,30,40和50nn。通过与具有低PD-1表达的对照T细胞进行比较,显着更高的装载力的应用降低了S / N比,这表明对这些测量的低负荷力小于20nn。使用免疫荧光确认PD-1的表达水平与破裂力值之间的相关性。通过使用抗体药物靶向表皮生长因子受体(EGFR)和表达EGFR分子(A431)的模型癌细胞进行类似的测定,以评估发育方法对各种抗体药物的通用应用,以及与此相同的结论获得了Nivolumab的案件。该方法可以应用于没有任何化学处理的活细胞,这允许本方法将各种抗体药物的亲和力与相同的单细胞进行比较。这些结果表明,本方法可用于从抗体和活细胞之间的结合力的观点来选择来自各种抗体药物的最有效候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号